Drug intelligence / Profile preview

trimethoprim + polymyxin B

Development stage
Approved
Lead developer
Allergan
Modality
Peptides, Small Molecules
Administration
Ophthalmic
01

Overview

**Trimethoprim + polymyxin B** is a fixed-dose topical ophthalmic antibacterial combination marketed as Polytrim. It contains trimethoprim, a selective reversible inhibitor of bacterial dihydrofolate reductase that blocks tetrahydrofolate synthesis and thereby impairs bacterial nucleic-acid and protein synthesis, plus polymyxin B, a cyclic lipopeptide antibiotic that disrupts bacterial cell-membrane permeability. The sterile ophthalmic solution contains trimethoprim 1 mg/mL and polymyxin B 10,000 units/mL and is approved for susceptible bacterial surface eye infections, including acute bacterial conjunctivitis and blepharoconjunctivitis. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/050567s028lbl.pdf))

Brand names
PolytrimSandoz Polytrimethoprim
Other names
polymyxin B + trimethoprimpolymyxin B sulfate + trimethoprim sulfatepolymyxin B/trimethoprimtrimethoprim + polymyxin Btrimethoprim sulfate + polymyxin B sulfatetrimethoprim/polymyxin B
02

Targets

DHFR (Dihydrofolate reductase)LPS (Lipopolysaccharide)

Beyond the preview

Go deeper on trimethoprim + polymyxin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trimethoprim + polymyxin B.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call